CEO in Danish Nuevolution, Alex Gouliaev, credits his employees for Amgen's offer to acquire the company for USD 167 million. He hopes that he and most staff members will continue their work under the new leadership, which is to speed up development in the Danish company.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.